3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Gastrointestinal
1
Conditions
Venous Thrombosis
2
Venous Thromboembolism
2
Pulmonary Embolism
2
Gastrointestinal Neoplasms
1
Interventions
Cyclophosphamide
390
Carboplatin
343
Gemcitabine
331
pembrolizumab
330
Cisplatin
327
Paclitaxel
295
Radiotherapy
292
Docetaxel
286
Bevacizumab
249
Rituximab
233
Capecitabine
222
Nivolumab
220
Dexamethasone
205
Fluorouracil
189
fludarabine
178
Oxaliplatin
177
Pemetrexed
153
Doxorubicin
152
Irinotecan
147
Etoposide
144
Leucovorin
143
Cytarabine
134
fludarabine phosphate
129
Bortezomib
129
Cetuximab
127
Lenalidomide
125
Filgrastim
120
Erlotinib Hydrochloride
119
Temozolomide
111
Ipilimumab
111
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Interventional
×
abelacimab
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled
NCT05171049
2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3
Terminated
1,150 enrolled